These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution. Grimm D; Büning H Hum Gene Ther; 2017 Nov; 28(11):1075-1086. PubMed ID: 28835125 [TBL] [Abstract][Full Text] [Related]
3. Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants. Rapti K; Maiakovska O; Becker J; Szumska J; Zayas M; Bubeck F; Liu J; Gerstmann E; Krämer C; Wiedtke E; Grimm D J Vis Exp; 2022 Oct; (188):. PubMed ID: 36342179 [TBL] [Abstract][Full Text] [Related]
4. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. Kienle E; Senís E; Börner K; Niopek D; Wiedtke E; Grosse S; Grimm D J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491297 [TBL] [Abstract][Full Text] [Related]
5. Next-generation AAV vectors for clinical use: an ever-accelerating race. Weinmann J; Grimm D Virus Genes; 2017 Oct; 53(5):707-713. PubMed ID: 28762205 [TBL] [Abstract][Full Text] [Related]
6. Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing. de Alencastro G; Pekrun K; Valdmanis P; Tiffany M; Xu J; Kay MA Hum Gene Ther; 2020 May; 31(9-10):553-564. PubMed ID: 32024384 [TBL] [Abstract][Full Text] [Related]
7. Machine-learning-guided Directed Evolution for AAV Capsid Engineering. Fu X; Suo H; Zhang J; Chen D Curr Pharm Des; 2024; 30(11):811-824. PubMed ID: 38445704 [TBL] [Abstract][Full Text] [Related]
8. Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors. El Andari J; Grimm D Biotechnol J; 2021 Jan; 16(1):e2000025. PubMed ID: 32975881 [TBL] [Abstract][Full Text] [Related]
9. Impact of the Assembly-Activating Protein on Molecular Evolution of Synthetic Adeno-Associated Virus Capsids. Herrmann AK; Große S; Börner K; Krämer C; Wiedtke E; Gunkel M; Grimm D Hum Gene Ther; 2019 Jan; 30(1):21-35. PubMed ID: 29978729 [TBL] [Abstract][Full Text] [Related]
10. Progress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy Vectors. Liu J; Koay TW; Maiakovska O; Zayas M; Grimm D Hum Gene Ther; 2023 May; 34(9-10):350-364. PubMed ID: 37082964 [TBL] [Abstract][Full Text] [Related]
11. A Robust and All-Inclusive Pipeline for Shuffling of Adeno-Associated Viruses. Herrmann AK; Bender C; Kienle E; Grosse S; El Andari J; Botta J; Schürmann N; Wiedtke E; Niopek D; Grimm D ACS Synth Biol; 2019 Jan; 8(1):194-206. PubMed ID: 30513195 [TBL] [Abstract][Full Text] [Related]
12. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Yang L; Li J; Xiao X Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025 [TBL] [Abstract][Full Text] [Related]
13. Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid. Martino RA; Wang Q; Xu H; Hu G; Bell P; Arroyo EJ; Sims JJ; Wilson JM J Virol; 2023 Jun; 97(6):e0017423. PubMed ID: 37199615 [TBL] [Abstract][Full Text] [Related]
14. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors. Lam AK; Frabutt D; Li L; Xiao W Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844 [TBL] [Abstract][Full Text] [Related]
15. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach. Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336 [TBL] [Abstract][Full Text] [Related]
16. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Shi W; Arnold GS; Bartlett JS Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765 [TBL] [Abstract][Full Text] [Related]